Biomaterial Database

A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. 2017

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Medical Center of The Graduate School, Nanchang University, Nanchang, China.

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of diseases, including simple steatosis, nonalcoholic steatohepatitis (NASH), liver cirrhosis and hepatocellular carcinoma. Lipotoxicity, insulin resistance (IR) and inflammation are involved in the disease process. Lipotoxicity promotes inflammation and IR, which in turn, increase adipocyte lipolysis and exacerbates lipotoxicity. Furthermore, IR and inflammation form a vicious circle, with each condition promoting the other and accelerating the development of NAFLD in the presence of lipotoxicity. As an integrator of inflammatory pathway networks, nuclear factor-kappa B (NF-κB) regulates expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and anti-inflammatory cytokines, such as adiponectin in NAFLD. In this review, the relationships between lipotoxicity, IR and inflammation in NAFLD are discussed, with particular emphasis on the inflammatory pathways.

UI	MeSH Term	Description	Entries
D007249	Inflammation	A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007333	Insulin Resistance	Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	Insulin Sensitivity,Resistance, Insulin,Sensitivity, Insulin
D008099	Liver	A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.	Livers
D008103	Liver Cirrhosis	Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008113	Liver Neoplasms	Tumors or cancer of the LIVER.	Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D005786	Gene Expression Regulation	Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.	Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006528	Carcinoma, Hepatocellular	A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409	Tumor Necrosis Factor-alpha	Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.	Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015398	Signal Transduction	The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.	Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal

Related Publications

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease.

March 2021, Immunity, inflammation and disease,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance.

September 2013, The Journal of endocrinology,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation.

January 2021, Journal of affective disorders,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Insulin resistance in nonalcoholic fatty liver disease.

June 2010, Current pharmaceutical design,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides.

November 2019, The New England journal of medicine,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Insulin resistance syndrome and nonalcoholic fatty liver disease.

January 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

May 2016, Clinics in liver disease,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease.

December 2020, Journal of clinical medicine,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Nonalcoholic fatty liver disease and insulin resistance in youth.

June 2007, Diabetes care,

Zhonge Chen, and Rong Yu, and Ying Xiong, and Fangteng Du, and Shuishan Zhu

Nonalcoholic fatty liver disease and insulin resistance in children.

December 2023, Clinical and experimental pediatrics,